Cancers, 2020.12(11), 3192-0, DOI: https://doi.org/10.3390/cancers12113192

9G Test TM Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening

Choe W, Chae J;Lee BH;Kim SH;Park S;Nimse S;Kim J;Warkad S;Song KS;Oh AC;Hong Y;Kim T

Abstract

Lung cancer is the most common cause of cancer-related deaths globally. Patients diagnosed at early-stage (0–I) have a higher survival rate than the metastasized stages (III–IV).
Thus, there is great potential to reduce mortality by diagnosing lung cancer at stage 0~I through community screening. LDCT is a promising method, but it has a high false-positive rate. Therefore, a biomarker test that can be used in combination with LDCT for lung cancer screening to reduce false-positive rates is highly awaited. The present study evaluated the applicability of 9G testTM Cancer/Lung test to detect stage 0~IV lung cancer. 9G testTM Cancer/Lung test detects stage I, stage II, stage III, and stage IV cancers with the sensitivities of 77.5%, 78.1%, 67.4%, and 33.3%, respectively, at the specificity of 97.3%. These results indicate that the 9G testTM Cancer/Lung can be used in conjunction with LDCT to screen lung cancer.

• DOI: https://doi.org/10.3390/cancers12113192
• ISBN or ISSN: 2072-6694

• 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
• This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.